Accuray Incorporated (NASDAQ:ARAY) CFO Kevin Waters sold 7,154 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $5.06, for a total value of $36,199.24. Following the sale, the chief financial officer now directly owns 335,087 shares of the company’s stock, valued at $1,695,540.22. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Accuray Incorporated (ARAY) opened at $5.25 on Monday. The company has a debt-to-equity ratio of 2.44, a quick ratio of 0.92 and a current ratio of 1.48. Accuray Incorporated has a twelve month low of $3.60 and a twelve month high of $6.00.
Accuray (NASDAQ:ARAY) last released its earnings results on Tuesday, October 24th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.02. The company had revenue of $91.00 million during the quarter, compared to analyst estimates of $88.26 million. Accuray had a negative return on equity of 55.18% and a negative net margin of 7.49%. Accuray’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.12) earnings per share. sell-side analysts anticipate that Accuray Incorporated will post -0.18 EPS for the current fiscal year.
A number of analysts have commented on the company. Lake Street Capital assumed coverage on Accuray in a report on Thursday. They set a “buy” rating and a $10.00 price objective for the company. Cowen reissued a “buy” rating and set a $9.00 price objective on shares of Accuray in a report on Friday, October 27th. Zacks Investment Research raised Accuray from a “sell” rating to a “hold” rating in a report on Tuesday, September 19th. Jefferies Group reissued a “buy” rating and set a $7.00 price objective on shares of Accuray in a report on Wednesday, August 9th. Finally, BTIG Research reissued a “hold” rating on shares of Accuray in a report on Thursday, August 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $6.82.
COPYRIGHT VIOLATION NOTICE: “Accuray Incorporated (ARAY) CFO Sells $36,199.24 in Stock” was first posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.com-unik.info/2017/12/04/accuray-incorporated-aray-cfo-sells-36199-24-in-stock.html.
Accuray Company Profile
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
What are top analysts saying about Accuray Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Accuray Incorporated and related companies.